External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>The company’s revenue (largely inline) was up 12%/3% YoY/QoQ on account of a 5% YoY increase in ASP (price hike and higher spares mix), and a 7%/2.5% YoY/QoQ growth in volumes (low base in Q4FY22).</li><li>ASP increased 1% QoQ led by price hikes in Jan’23 on account of input cost pass-through and to comply with regulatory norms.</li><li>EBITDA beat ours/consensus estimates by 9%/10% respectively and was up 31%/17%% YoY/QoQ while EBITDA margin at 13% (vs. 12%/11% in Q3FY23/Q4FY22) beat ours/consensus estimate of 12%.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The company’s revenue (largely inline) was up 12%/3% YoY/QoQ on account of a 5% YoY increase in ASP (price hike and higher spares mix), and a 7%/2.5% YoY/QoQ growth in volumes (low base in Q4FY22).ASP increased 1% QoQ led by price hikes in Jan’23 on account of input cost pass-through and to comply with regulatory norms.EBITDA beat ours/consensus estimates by 9%/10% respectively and was up 31%/17%% YoY/QoQ while EBITDA margin at 13% (vs. 12%/11% in Q3FY23/Q4FY22) beat ours/consensus estimate of 12%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Hero Motocorp - Strong Q4; Increasing Focus on Market Share Recovery

Consumer Analyst / Channel Surveillance Specialist, Trudence Capital Advisors

Pranav Bhavsar

Consumer Analyst / Channel Surveillance Specialist

Trudence Capital Advisors

Trudence Capital Advisors Private Limited is a SEBI-registered Research Analyst, holding SEBI registration number INH000015747. Our firm is dedicated to providing independent and unbiased research on Indian mid to large-cap companies. Trudence Capital is known for its counter-consensus views, with a focus on forensic research and on-ground primary investigations. Our research approach is thorough, involving detailed analysis of accounting practices and governance, alongside extensive channel checks.

Independent & Unbiased Research

<ul>
<li>Strong demand for <a href="https://www.smartkarma.com/entities/eicher-motors-ltd" target="_blank" data-smartkarma-citation="entities:18316:1" rel="noopener">Eicher Motors (EIM IN)</a> 's Royal Enfield bikes with returning customers.</li>
<li>The model "Hunter" is expanding the market and attracting a new set of customers.</li>
<li>Royal Enfield entering a new growth phase with new launches and customer service focus.</li>
</ul>


Strong demand for Eicher Motors (EIM IN) 's Royal Enfield bikes with returning customers.
The model "Hunter" is expanding the market and attracting a new set of customers.
Royal Enfield entering a new growth phase with new launches and customer service focus.


Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mankind-pharma-ltd" target="_blank" data-smartkarma-citation="entities:36389:1" rel="noopener">Mankind Pharma (6596876Z IN)</a> is looking to raise up to US$526m in its IPO by selling 40.06m shares at a price range of INR 1026 to INR 1080 per share.</li>
<li>The company has allocated 12.02m shares to anchor investors at INR 1080/share. That list includes marquee names and the lock-up reduces near-term float.</li>
<li>The IPO opens on 25 April and will close on 27 April. Shares are expected to start trading on 9 May and there are no near-term index inclusions expected.</li>
</ul>



Mankind Pharma (6596876Z IN) is looking to raise up to US$526m in its IPO by selling 40.06m shares at a price range of INR 1026 to INR 1080 per share.
The company has allocated 12.02m shares to anchor investors at INR 1080/share. That list includes marquee names and the lock-up reduces near-term float.
The IPO opens on 25 April and will close on 27 April. Shares are expected to start trading on 9 May and there are no near-term index inclusions expected.


Mankind Pharma: IPO Details & Index Inclusion

External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Two-wheelers continued their weak trend even for Q4 with 2W industry production declining by 5% QoQ in Q4</li><li>While domestic 2W sales declined 7% QoQ, 2W exports further declined by 17% QoQ in Q4</li><li>On the other hand, while PV production was up 12% QoQ, CV industry production was up 23% on a QoQ basis in Q4</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Two-wheelers continued their weak trend even for Q4 with 2W industry production declining by 5% QoQ in Q4While domestic 2W sales declined 7% QoQ, 2W exports further declined by 17% QoQ in Q4On the other hand, while PV production was up 12% QoQ, CV industry production was up 23% on a QoQ basis in Q4Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>We expect Revenue/EBITDA/PAT of Auto OEMs under our coverage to grow at 19%/29%/29% YoY in Q4FY23.</li><li>On a sequential basis, too, we expect Auto OEMs to register a growth of 8%/11%/11%, which would be led by double-digit volume growth in the PV/CV segment (though this will be partially offset by lower 2W sales on account of lower exports).</li><li>EBITDA margins are expected to expand both YoY/QoQ due to a richer product mix, absorption of price hikes, and marginally lower RM costs.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We expect Revenue/EBITDA/PAT of Auto OEMs under our coverage to grow at 19%/29%/29% YoY in Q4FY23.On a sequential basis, too, we expect Auto OEMs to register a growth of 8%/11%/11%, which would be led by double-digit volume growth in the PV/CV segment (though this will be partially offset by lower 2W sales on account of lower exports).EBITDA margins are expected to expand both YoY/QoQ due to a richer product mix, absorption of price hikes, and marginally lower RM costs.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Auto Q4fy23 Preview - Improved Product Mix, Moderation in Rm Costs to Drive Margin Growth

India

Hero MotoCorp Ltd. designs, manufactures and distributes motorcycles. The Company's products also include motorcycle parts and accessories.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Hero Motocorp (HMCL IN)

Eicher Motors (EIM IN) | Ramping Up

Our dealer interaction indicates strong demand for Royal Enfield bikes with returning customers, Hunter is expanding the market, and focus on...

Pranav Bhavsar

Mankind Pharma: IPO Details & Index Inclusion

Mankind Pharma is looking to raise up to US$526m in its IPO by selling 40.06m shares at INR 1080/share. 12.02m shares have been allocated to anchor...

Brian Freitas

Autos: Growth rates set to normalise

Two-wheelers continued their weak trend even for Q4 with 2W industry production declining by 5% QoQ in Q4. While domestic 2W sales declined 7% QoQ

HDFC Securities

Auto Q4fy23 Preview - Improved Product Mix, Moderation in Rm Costs to Drive Margin Growth

EBITDA margins are expected to expand both YoY/QoQ due to a richer product mix, absorption of price hikes, and marginally lower RM costs.

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hero Motocorp - Strong Q4; Increasing Focus on Market Share Recovery

The company’s revenue (largely inline) was up 12%/3% YoY/QoQ on account of a 5% YoY increase in ASP (price hike and higher spares mix) and a 7%...

Axis Direct

Eicher Motors (EIM IN) | Ramping Up

Our dealer interaction indicates strong demand for Royal Enfield bikes with returning customers, Hunter is expanding the market, and focus on...

Pranav Bhavsar

Mankind Pharma: IPO Details & Index Inclusion

Mankind Pharma is looking to raise up to US$526m in its IPO by selling 40.06m shares at INR 1080/share. 12.02m shares have been allocated to anchor...

Brian Freitas

Autos: Growth rates set to normalise

Two-wheelers continued their weak trend even for Q4 with 2W industry production declining by 5% QoQ in Q4. While domestic 2W sales declined 7% QoQ

HDFC Securities

Auto Q4fy23 Preview - Improved Product Mix, Moderation in Rm Costs to Drive Margin Growth

EBITDA margins are expected to expand both YoY/QoQ due to a richer product mix, absorption of price hikes, and marginally lower RM costs.

Axis Direct